Allurion reports weight loss breakthrough at obesity congress

NATICK, Mass. – Allurion Technologies, Inc. (NYSE: ALUR), a developer of weight loss therapies with impressive gross profit margins of 67%, showcased new studies at the European Congress on Obesity in Malaga, Spain, demonstrating significant weight loss and muscle mass preservation using its Allurion Program, which includes a swallowable gastric balloon and a virtual care suite. According to InvestingPro analysis, while the company maintains strong margins, it faces significant operational challenges with a substantial debt burden and rapid cash burn rate.

Recent data presented from a study involving 138 patients indicated that using the Allurion Virtual Care Suite (VCS) alongside normal dosing of GLP-1 medications resulted in an average lean body mass increase of 6.1% and a muscle mass increase of 6.4%, with a fat mass reduction of 10.2% after four months. This suggests that Allurion’s AI-driven behavioral support can help maintain muscle mass during GLP-1 therapy. Despite these promising clinical results, InvestingPro data shows the company’s revenue declined by 40% in the last twelve months, with analysts not expecting profitability this year.

Another study involving 60 patients treated with the Allurion Balloon and semaglutide, a GLP-1 medication, reported an average body weight reduction of 21.2% over ten months. These results are comparable to those achieved with bariatric surgery, offering an alternative treatment for patients with severe obesity.

Dr. Roberta Ienca, who oversaw the study, stated that the combination of the Allurion Program with semaglutide represents a significant advancement in weight loss, potentially offering a sustainable solution for weight management.

Further studies presented at the congress highlighted the effectiveness of the Allurion Program in weight loss. A comparison of 43 patients using the VCS with GLP-1s showed an average body weight reduction of 17.3% at nine months, surpassing outcomes from other U.S. studies without the VCS. Moreover, a large single-center experience involving 2,000 patients who used the Allurion Program alone showed an average weight reduction of 12.4% and a muscle mass increase of 9.8% after six months.

These findings underscore the potential of Allurion’s non-surgical weight loss solutions and their scalability for obesity clinics. The Allurion Program combines a swallowable gastric balloon, a mobile app, and an AI platform designed to personalize and monitor weight loss therapy for patients.

Allurion emphasizes that the Allurion Gastric Balloon is still under investigation in the United States and has not yet received regulatory approval. The company’s forward-looking statements reflect their current expectations based on information available and are subject to risks and uncertainties that could affect actual future results.

This article is based on a press release statement from Allurion Technologies, Inc.

In other recent news, Allurion Technologies has announced several significant developments. The company reported a decline in revenue for the fourth quarter of 2024, with earnings dropping to $5.6 million from $8.2 million in the same quarter the previous year. Despite this, Allurion has projected a revenue forecast of $30 million for 2025, slightly down from $32 million in 2024. In a related financial move, Allurion successfully raised $15 million in net cash through equity offerings in the first quarter of 2025, which is expected to fund operations into 2026.

Additionally, Allurion Technologies gained stockholder approval for the repricing of warrants and amendments to its Note Purchase Agreement, which could impact its financial instruments. The company also received clearance from the French National Agency for the Safety of Medicines and Health Products to resume sales of its Allurion Balloon in France. This comes after a period of suspended sales in the French market.

Analyst firm Chardan Capital Markets has maintained a Neutral rating on Allurion’s stock with a price target of $2.50, reflecting tempered expectations for the company’s performance. Meanwhile, TD Cowen highlighted that Allurion is expected to be less impacted by new U.S. tariff measures due to its domestic manufacturing operations. These developments underscore a period of transition and strategic shifts for Allurion Technologies as it navigates its financial landscape and market challenges.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.